WikipediaRead full entry
Crimean–Congo hemorrhagic fever
|Crimean-Congo hemorrhagic fever|
|Classification and external resources|
Isolated male patient diagnosed with Crimean-Congo hemorrhagic fever
Crimean–Congo hemorrhagic fever (CCHF) is a widespread tick-borne viral disease, a zoonosis of domestic animals and wild animals, that may affect humans. The pathogenic virus, especially common in East and West Africa, is a member of the Bunyaviridae family of RNA viruses. Clinical disease is rare in infected mammals, but commonly severe in infected humans, with a 30% mortality rate. Outbreaks of illness are usually attributable to handling infected animals or people.
Signs and symptoms
Typically, after a 1–3 day incubation period following a tick bite (5–6 days after exposure to infected blood or tissues), flu-like symptoms appear, which may resolve after one week. In up to 75% of cases, however, signs of hemorrhage appear within 3–5 days of the onset of illness in case of bad containment of the first symptoms: first mood instability, agitation, mental confusion and throat petechiae, then soon nosebleeds, rainbow urine and vomiting, and black stools. The liver becomes swollen and painful. Disseminated intravascular coagulation may occur as well as acute kidney failure and shock, and sometimes acute respiratory distress syndrome. Patients usually begin to show signs of recovery after 9–10 days from when the symptoms appear, however 30% of the cases result in death on the second week of the illness.
The genome is circular, ambisense RNA in three parts - Small (S), Middle (M) and Large (L). The L segment is 11–14.4 kilobases in length while the M and S segments are 4.4–6.3 and 1.7–2.1 kilobases long respectively. The L segment encodes the RNA polymerase; the M segment encodes the envelope proteins (Gc and Gn); and the S segment encodes the nucleocapsid protein. The envelope protein is initially translated as a glycoprotein precursor which is then cleaved into two smaller proteins.
CCHFV is the most genetically diverse of the arboviruses: Its nucleotide sequences frequently differ between isolates with a range of 20% of the based being different (viral S segment) to 31% (viral segment M). Viruses with diverse sequences can be found within the same geographic area; closely related viruses have been isolated widely separated regions. This suggests that viral dispersion has occurred possibly by ticks carried on migratory birds or through the international livestock trade. Reassortment among genome segments during coinfection of ticks or vertebrates seems likely to have played a role in generating diversity in this virus.
Based on the sequence data seven genotypes have been recognised: Africa 1 (Senegal), Africa 2 (Democratic Republic of the Congo and South Africa), Africa 3 (southern and western Africa), Europe 1 (Albania, Bulgaria, Kosovo, Russia and Turkey), Europe 2 (Greece), Asia 1 (the Middle East, Iran and Pakistan) and Asia 2 (China, Kazakhstan, Tajikistan and Uzbekistan).
The virons are 80–120 nanometers (nm) in diameter and are pleomorphic. There are no host ribosomes within the viron. Each viron contains three copies of the genome. The envelope is single layered and is formed from a lipid bilayer 5 nm thick. It has no protrusions. The envelope proteins form small projections ~5–10 nm long. The nucleocapsids are filamentous and circular with a length of 200–3000 nm.
This virus appears to have evolved 3100–3500 years ago. The mutation rates for the three parts of the genome were estimated to be: 1.09×10−4, 1.52×10−4 and 0.58×10−4 substitutions/site/year for the S, M, and L segments respectively.
The virus has been isolated from at least 31 different species of ticks from the genera Haemaphysalis and Hyalomma. Sporadic infection of people is usually caused by Hyalomma tick bite. Clusters of illness typically appear after people treat, butcher or eat infected livestock, particularly ruminants and ostriches. Outbreaks have occurred in clinical facilities or in abattoirs where health workers have been exposed to infected human or animal blood and fomites.
The causative organism is found in Asia, Eastern Europe, the Middle East, a belt across central Africa and South Africa and Madagascar (see map ) The main environmental reservoir for the virus is small mammals (particularly European Hare, Middle-African hedgehogs and multimammate rats). Ticks carry the virus to domestic animal stock. Sheep, goats and cattle develop high titers of virus in blood, but tend not to fall ill. Birds are generally resistant with the exception of ostriches.
Tick species that have been identified as infected with this virus include Argas reflexus, Hyalomma anatolicum, Hyalomma detritum, Hyalomma marginatum marginatum and Rhipicephalus sanguineus.Both working with humans and animals infected from Congo–Crimean Hemorrhagic fever usually transmit the virus to other humans.
Where mammalian tick infection is common, agricultural regulations require de-ticking farm animals before transportation or delivery for slaughter. Personal tick avoidance measures are recommended, such as use of insect repellents, adequate clothing and body inspection for adherent ticks.
Since the 1970s, several vaccine trials around the world against CCHF have been scrapped due to high toxicity. The only available and probably somewhat efficacious CCHF vaccine is an inactivated antigen preparation currently used in Bulgaria. More modern vaccines are under development,but the sporadic nature of the disease even in endemic countries suggests that large trials of vaccine efficacy will be difficult to perform. Finding volunteers may prove challenging,given the growing resistance of populations to vaccines against contagious diseases such as measles or poliomyelitis. The number of people to be vaccinated and the length of time they would have to be followed to confirm protection would have to be carefully defined.Alternatively, many scientists appear to believe that treatment of CCHF with ribavirin is more practical than prevention, but some recently conducted clinical trials appear to counter assumptions of drug efficacy. Immunoglobulin preparations have been used for more than 30 years to prevent and treat CCHF in Bulgaria, but few data have been published, and their efficacy remains unproven. Although recent developments in antibody engineering have raised hopes for novel mAb therapies, this approach remains in its infancy.
In 2011, a Turkish research team led by Erciyes University has successfully developed the first non-toxic preventive vaccine, which passed clinical trials. The vaccine is pending approval by the FDA.
Treatment is primarily symptomatic and supportive, as there is no established specific treatment. Ribavirin is effective in vitro and has been used during outbreaks, but there is no trial evidence to support its use.
A Turkish research team led by Refik Saydam Health Institute has developed treatment-serum derived from blood of several CCHF-patients, which have been proven to be 90% effective in CCHF-patients.
Crimean–Congo hemorrhagic fever occurs most frequently among agricultural workers following the bite of an infected tick, and to a lesser extent among slaughterhouse workers exposed to the blood and tissues of infected livestock and medical personnel through contact with the body fluids of infected patients.
On July 28, 2005 authorities reported 41 cases of CCHF in Turkey's Yozgat Province, with one death. As of August 2008, a total of 50 people were reported to have lost their lives in various cities in Turkey due to CCHF. 3128 Crimean–Congo hemorrhagic fever cases with 5% of case-fatality rate have been reported by the Ministry of Health of Turkey between 2002–2008.
CCHF is also endemic in Kosovo. Institute of Public Health of Kosovo reported 228 cases of CCHF in the Republic of Kosovo from the year 1995 to 2013, with the mortality rate of disease being 25.5%.
In September 2010 an outbreak has been reported in Pakistan's Khyber Pakhtunkhwa province. Poor diagnosis and record keeping has caused the extent of the outbreak to be uncertain, though some reports indicate over 100 cases, with a case-fatality rate above 10%.
In January 2011, the disease has been reported in Gujarat, India, with 4 reported deaths, which consisted of the patient along with the doctor and the nurse who treated the patient.
As of May 2012, 71 people are reported to have contracted the disease in Iran, resulting in 8 fatalities.
In October 2012, a British man died from the disease at the Royal Free Hospital in London. He had earlier been admitted to Gartnavel General Hospital in Glasgow after returning on a flight from Kabul in Afghanistan.
On August 16, 2013, a farmer from Agago, Uganda was treated at Kalongo Hospital for a confirmed CCHF infection. Additionally, the deaths of three other people in the northern region were suspected to have been caused by the virus. Six people who had come in contact with the Agago man were placed under observation, and released after showing no symptoms in two weeks. Another unrelated suspected CCHF patient as admitted to Mulago Hospital on the same day. The Ministry of Health announced on the 19th that the outbreak was under control, but the second patient, a 27-year old woman from Nansana, died on the 21st. She is believed to have contracted the virus from her husband, who returned to Kampala after being treated for CCHF in Juba, South Sudan. In the recent years cases have been diagnosed in Kazakhstan. Ten people, including an ambulance crew, were admitted on Jun 23rd 2014 to Hospital in Southern Kazakhstan on suspicions of carrying the virus. In Pakistan, at Hayatabad Medical Complex (HMC) an 8th person was infected from [Crimean-]Congo hemorrhagic fever [CCHF] on July 11th 2014. The eight patients, including a nurse and 6 Afghan nationals, died in the period April-July 2014.
A case reported in the 12th century of a hemorrhagic disease from what is now Tajikistan may have been the first known case of Crimean–Congo hemorrhagic fever. Soviet scientists first identified the disease they called Crimean hemorrhagic fever in 1944 and established its viral etiology by passage of the virus through human "volunteers" (fatality rate unreported), but were unable to isolate the agent at that time. In June 1967, Soviet virologist Mikhail Chumakov registered an isolate from a fatal case that occurred in Samarkand (on the ancient Silk Road in Central Asia, not the Crimea) in the Catalogue of Arthropod-borne Viruses.
Four months earlier, virologists Jack Woodall, D Simpson and others had published initial reports on a virus they called the Congo virus, first isolated in 1956 by physician Ghislaine Courtois, head of the Provincial Medical Laboratory, Stanleyville, Belgian Congo. Strain V3010, isolated by Courtois, was sent to the Rockefeller Foundation Virus Laboratory (RFVL) in New York City and found to be identical to another strain from Uganda, but to no other named virus at that time. Chumakov later sent his strain to the RFVL, where it was found to be identical to the Congo virus.
The International Committee on Taxonomy of Viruses proposed the name Congo–Crimean hemorrhagic fever virus, but the Soviets insisted on Crimean–Congo hemorrhagic fever virus. Against all principles of scientific nomenclature based on priority of publication, it was adopted as the official name in 1973 in possibly the first instance of a virus losing its name to politics and the Cold War. However, since then Congo–Crimean or just Congo virus has been used in many reports, which would be missed in searches of medical databases using the official name. These reports include records of the occurrence of the virus or antibodies to the virus from Greece, Portugal, South Africa, Madagascar (the first isolation from there), the Maghreb, Dubai, Saudi Arabia, Kuwait and Iraq.
- Bente DA, Forester NL, Watts DM, McAuley AJ, Whitehouse CA, Bray M (2013) Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res pii: S0166-3542(13)00193-9. doi: 10.1016/j.antiviral.2013.07.006.
- Carroll SA, Bird BH, Rollin PE, Nichol ST (2010) Ancient common ancestry of Crimean-Congo hemorrhagic fever virus. Mol Phylogenet Evol 55(3):1103–1110
- Mehravaran A, Moradi M, Telmadarraiy Z, Mostafavi E, Moradi AR, Khakifirouz S, Shah-Hosseini N, Varaie FS, Jalali T, Hekmat S, Ghiasi SM, Chinikar S (2012) Molecular detection of Crimean–Congo haemorrhagic fever (CCHF) virus in ticks from southeastern Iran. Ticks Tick Borne Dis pii: S1877-959X(12)00064-7. doi: 10.1016/j.ttbdis.2012.06.006
- Xiao, X.; Feng, Y.; Zhu, Z.; Dimitrov, D. S. (2011). "Identification of a putative Crimean–Congo hemorrhagic fever virus entry factor". Biochem. Biophys. Res. Commun. 411 (2): 253–258. doi:10.1016/j.bbrc.2011.06.109. PMID 21723257.
- Keshtkar-Jahromi M, Kuhn JH, Christova I, Bradfute SB, Jahrling PB, Bavari S.. Crimean-Congo hemorrhagic fever: Current and future prospects of vaccines and therapies. Antiviral Res. 2011 Mar; 90(2): 85-92. Cited in PubMed; PMID 21362441.
- Watts DM, Ussery MA, Nash D, Peters CJ. (1989). "Inhibition of Crimean–Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin". Am J Trop Med Hyg. 41 (5): 581–5. PMID 2510529.
- Ergönül Ö, Celikbas A, Dokuzoguz B, et al. (2004). "The chacteristics of Crimean–Congo hemorrhagic fever in a recent outbreak in Turkey and the impact of oral ribavirin therapy". Clin Infect Dis 39 (2): 285–9. doi:10.1086/422000. PMID 15307042.
- Fajs L,Jakupi Xh, Ahmeti S, Humolli I, Dedushaj I, Avšič-Županc T (2014)Molecular Epidemiology of Crimean-Congo Hemorrhagic Fever Virus in Kosovo. PLoS Negl Trop Dis January 09, 2014 DOI: 10.1371/journal.pntd.0002647. 
- http://www.indianexpress.com/news/deadly-virus-makes-first-appearance-in-india-kills-three-in-gujarat originated from sanand /739292/
- Biryabarema, Elias (17 August 2013). "Three die in Uganda from Ebola-like fever: Health Ministry". Yahoo News. Reuters. Retrieved 16 August 2013.
- Otto, Alex (22 August 2013). "High Alert Over Crimean Fever". The Observer (Kampala). Retrieved 26 August 2013.
- Khan, Hidayat. "Stemming outbreaks: Eighth patient dies of Congo hemorrhagic fever at HMC". Retrieved 13 July 2014.
- Chumakov, 1947 INCOMPLETE
- Chumakov MP, Butenko AM, Shalunova NV, Mart'ianova LI, Smirnova SE, Bashkirtsev IuN, Zavodova TI, Rubin SG, Tkachenko EA, Karmysheva VIa, Reingol'd VN, Popov GV, Savinov AP (May–June 1968). "New data on the viral agent of Crimean hemorrhagic fever". Vopr Virusol (in Russian) 13 (3): 377. PMID 4235803.
- Simpson DI, Knight EM, Courtois G, Williams MC, Weinbren MP, Kibukamusoke JW (February 1967). "Congo virus: a hitherto undescribed virus occurring in Africa. I. Human isolations—clinical notes". East Afr Med J 44 (2): 86–92. PMID 6040759.
- Woodall JP, Williams MC, Simpson DI (February 1967). "Congo virus: a hitherto undescribed virus occurring in Africa. II. Identification studies". East Afr Med J 44 (2): 93–8. PMID 6068614.
- Casals J (May 1969). "Antigenic similarity between the virus causing Crimean hemorrhagic fever and Congo virus". Proc Soc Exp Biol Med 131 (1): 233–6. doi:10.3181/00379727-131-33847. PMID 5770109.
- Crowcroft NS, Morgan D, Brown D (March 2002). "Viral haemorrhagic fevers in Europe—effective control requires a co-ordinated response". Euro Surveill 7 (3): 31–2. PMID 12631941.
- Al-Tikriti SK, Al-Ani F, Jurji FJ, Tantawi H, Al-Moslih M, Al-Janabi N, Mahmud MI, Al-Bana A, Habib H, Al-Munthri H, Al-Janabi S, AL-Jawahry K, Yonan M, Hassan F, Simpson DI (1981). "Congo/Crimean haemorrhagic fever in Iraq". Bull World Health Organ 59 (1): 85–90. PMC 2396030. PMID 6790183.
- Okorie TG (March 1991). "Comparative studies on the vector capacity of the different stages of Amblyomma variegatum Fabricius and Hyalomma rufipes Koch for Congo virus, after intracoelomic inoculation". Vet Parasitol 38 (2–3): 215–23. doi:10.1016/0304-4017(91)90131-e. PMID 1907050.